<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722471</url>
  </required_header>
  <id_info>
    <org_study_id>IB-1201</org_study_id>
    <nct_id>NCT04722471</nct_id>
  </id_info>
  <brief_title>Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.</brief_title>
  <acronym>CycloCT</acronym>
  <official_title>Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy, in terms of progesterone levels and clinical&#xD;
      outcomes, of two different presentations of micronized vaginal progesterone (400 mg vs. 200&#xD;
      mg) used in endometrial preparation in artificial cycle (AC) for embryo transfer.&#xD;
&#xD;
      This is a non-inferiority, retrospective case-control study, with at least 200 cycles&#xD;
      analyzed (at least 100 per arm) and the primary outcome is the serum progesterone level on&#xD;
      the day of the embryo transfer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Actual">March 17, 2021</completion_date>
  <primary_completion_date type="Actual">March 3, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum progesterone level</measure>
    <time_frame>On the day of embryo transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for additional progesterone supplementation</measure>
    <time_frame>assessed on the day of the embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical results (ongoing pregnancy and miscarriage rate)</measure>
    <time_frame>assessed on the day of the pregnancy test and during the pregnancy evolution</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">347</enrollment>
  <condition>Luteal Phase Defect</condition>
  <arm_group>
    <arm_group_label>400 mg</arm_group_label>
    <description>Treatments where 400 mg tablet presentation of micronized vaginal progesterone was used, the protocol being one vaginal tablet twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg</arm_group_label>
    <description>Treatments where 200 mg tablet presentation of micronized vaginal progesterone was used, the protocol being two vaginal tablets twice a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginally administered progesterone</intervention_name>
    <description>The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)</description>
    <arm_group_label>200 mg</arm_group_label>
    <arm_group_label>400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population will be selected among those patients who have undergone embryo transfer&#xD;
        treatment with endometrial preparation in a artificial cycle at the Instituto Bernabeu.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with primary or secondary infertility undergoing endometrial preparation for&#xD;
             an embryo transfer using standard doses of oral or transdermal estrogens.&#xD;
&#xD;
          -  Age between 18 and 50 years.&#xD;
&#xD;
          -  Normal uterine cavity verified by imaging techniques.&#xD;
&#xD;
          -  Serum progesterone documented on the day of embryo transfer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of endometritis.&#xD;
&#xD;
          -  Patients diagnosed with Asherman's syndrome.&#xD;
&#xD;
          -  Patients with a different supplementation regimen or doses than those of the study&#xD;
             groups.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquín Llácer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Bernabeu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Labarta E, Mariani G, Holtmann N, Celada P, Remohí J, Bosch E. Low serum progesterone on the day of embryo transfer is associated with a diminished ongoing pregnancy rate in oocyte donation cycles after artificial endometrial preparation: a prospective study. Hum Reprod. 2017 Dec 1;32(12):2437-2442. doi: 10.1093/humrep/dex316. Erratum in: Hum Reprod. 2018 Jan 1;33(1):178.</citation>
    <PMID>29040638</PMID>
  </results_reference>
  <results_reference>
    <citation>Labarta E, Mariani G, Paolelli S, Rodriguez-Varela C, Vidal C, Giles J, Bellver J, Cruz F, Marzal A, Celada P, Olmo I, Alamá P, Remohi J, Bosch E. Impact of low serum progesterone levels on the day of embryo transfer on pregnancy outcome: a prospective cohort study in artificial cycles with vaginal progesterone. Hum Reprod. 2021 Feb 18;36(3):683-692. doi: 10.1093/humrep/deaa322.</citation>
    <PMID>33340402</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Joaquín Llácer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Frozen embryo transfer</keyword>
  <keyword>endometrial preparation</keyword>
  <keyword>artificial cycle</keyword>
  <keyword>progesterone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The information collected in the study will always be treated as grouped data and never as individual or personal data, thus maintaining anonymity and confidentiality.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

